A comparison of the effect of anticancer drugs, idarubicin and adriamycin, on soluble chromatin.
The biological activity of an anticancer agent is related to its physicochemical interaction with biological receptors. In the present study we have investigated and compared the affinity and mode of action of two potent anticancer drugs, adriamycin and idarubicin on soluble chromatin using ultraviolet/visible and fluorescence spectroscopy, hydroxyapatite (HAP) chromatography and gel electrophoresis techniques. The results show that addition of various concentrations of drugs to chromatin solution individually, reduced both absorbance and fluorescence emission intensity of chromatin and precipitated it in a dose dependent manner, however, the extent of reduction was different for two drugs used. This effect was also observed on the histone gel patterns of the drug treated samples revealing that the chromatin is less affected by idarubicin compared to adriamycin implying higher aggregation of chromatin with the former. As hydroxyapatite chromatograms show, histone H1 represented the highest drug binding activity. The results suggest that although adriamycin and idarubicin are both grouped anthracycline antibiotic anticancer drugs, they differ considerably on their binding affinity to cellular chromatin.
Zahraei
Zohreh
Z
Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran.
Rabbani-Chadegani
Azra
A
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001665:Binding Sites; D002843:Chromatin / Q000187:drug effects* / Q000378:metabolism; D002845:Chromatography; D004317:Doxorubicin / Q000494:pharmacology*; D004591:Electrophoresis, Polyacrylamide Gel; D015255:Idarubicin / Q000494:pharmacology*; D008099:Liver / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D012995:Solubility; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; D002843:Chromatin; D004317:Doxorubicin; D015255:Idarubicin